Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)

PHASE3CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 21, 2009

Primary Completion Date

January 24, 2013

Study Completion Date

January 24, 2013

Conditions
Short Bowel Syndrome
Interventions
DRUG

teduglutide

0.05 mg/kg/day subcutaneously taken once per day for 24 months

Trial Locations (23)

2100

Rigshospitalet, Copenhagen

10029

Mount Sinai Medical Center, New York

13353

Med. Klinik m.S. Hepatologie und Gastroenterologie, Berlin

15213

University Of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennslyvania, Philadelphia

28041

Hospital Universitario 12 de Octubre, Madrid

37232

Vanderbilt University Medical Center, Nashville

44195

Cleveland Clinic Foundation, Cleveland

72076

Universitaetsklinikum Tuebingen Medizinische Klinik I, Tübingen

80131

Azienda Universitaria Policlinico Federico II, Napoli

92037

Scripps Clinic & Research Foundation, La Jolla

T5H 4B9

Royal Alexandra Hospital, Edmonton

M5B1W8

St. Michael's Hospital, Toronto

M5G 2N2

University Health Network - Toronto General Hospital, Toronto

Unknown

Hôpital Beaujon, Clichy

Hopital de l'Archet 2, Nice

90-531

Wojewodzki Szpital Specjalistyczny im. M. Pirogowa, Pracownia Leczenia Zywieniowego, Lodz

20-090

Samodzielny Publiczny Szpital Kliniczny nr 4, Klinika Chirurgii Ogolnej i Transplantacyjnej, Lublin

10-651

Pracownia Żywienia Klinicznego, Olsztyn

00-416

Samodzielny Publiczny Szpital Kliniczny-Im.prof W.Orłowskiego CMKP, Warsaw

08907

Hospital Universitario de Bellvitge, Barcelona

HA13UJ

St. Marks Hospital, Harrow

WC1E 6DB

University College London Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Nycomed Germany GmbH

INDUSTRY

lead

Shire

INDUSTRY

NCT00930644 - Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS) | Biotech Hunter | Biotech Hunter